从病毒诱导细胞衰老看长新冠的中医病机演变
摘要
球公共卫生问题。新型冠状病毒感染进入恢复期后，常会出现多个系统的症状，称之为新型冠状病毒感染后长期症
状，简称为“长新冠”（Long Covid）。近期研究发现细胞衰老，一种年龄相关的细胞状态，不仅是新冠急性期引起
高炎症反应的关键调节因子，也可能导致了长新冠的病机。而SARS-CoV-2可以通过多种机制诱发细胞衰老，即病
毒诱导衰老（VIS）。中医中药对COVID-19的诊治贯穿始终。在进入恢复期，尤其是长新冠的患者，中医对其辨治
论治更具有独特的优势。现将SARS-CoV-2诱导细胞衰老的机制及衰老相关因子对长新冠的影响和由此引起的中医
辨证论治进展作一综述。
关键词
全文:
PDF参考
[1]ELY E W, BROWN L M, FINEBERG H V, et al.
Long Covid Defined[J]. N Engl J Med, 2024,391(18):1746-
1753.
[2]SHAH W, HILLMAN T, PLAYFORD E D, et
al. Managing the long term effects of covid-19: summary
of NICE, SIGN, and RCGP rapid guideline[J]. BMJ,
2021,372:n136.
[3]SCHMITT C A, TCHKONIA T, NIEDERNHOFER
L J, et al. COVID-19 and cellular senescence[J]. Nat Rev
Immunol, 2023, 23(4):251-263.
[4]《中医药治疗新型冠状病毒感染核酸/抗原转阴
后常见症专家共识》发布[J].天津中医药，2023，40（2）：
149.
[5]HERRANZ N, GIL J. Mechanisms and functions of
cellular senescence[J]. J Clin Invest, 2018,128(4):1238-1246.
[6]GORGOULIS V, ADAMS P D, ALIMONTI A,
et al. Cellular Senescence: Defining a Path Forward[J]. Cell,
2019,179(4):813-827.
[7]CHAIB S, TCHKONIA T, KIRKLAND J L. Cellular
senescence and senolytics: the path to the clinic[J]. Nat Med,
2022,28(8):1556-1568.
[8]ISKE J, SEYDA M, HEINBOKEL T, et al. Senolytics
prevent mt-DNA-induced inflammation and promote
the survival of aged organs following transplantation[J]. Nat
Commun, 2020,11(1):4289.
[9]CHU X, RAJU R P. Regulation of NAD(+)
metabolism in aging and disease[J]. Metabolism, 2022, 126:
154923.
[10]XU M, PIRTSKHALAVA T, FARR J N, et al.
Senolytics improve physical function and increase lifespan in
old age[J]. Nat Med, 2018,24(8):1246-1256.
[11]EBERT T, TRAN N, SCHURGERS L, et al.
Ageing - Oxidative stress, PTMs and disease[J]. Mol Aspects
Med, 2022, 86:101099.
[12]TRIPATHI U, NCHIOUA R, PRATA L, et al.
SARS-CoV-2 causes senescence in human cells and exacerbates
the senescence-associated secretory phenotype through TLR-
3[J]. Aging (Albany NY), 2021,13(18):21838-21854.
[13]LEE S, YU Y, TRIMPERT J, et al. Virus-induced
senescence is a driver and therapeutic target in COVID-19[J].
Nature, 2021,599(7884):283-289.
[14]BARTLESON J M, RADENKOVIC D,
COVARRUBIAS A J, et al. SARS-CoV-2, COVID-19
and the Ageing Immune System[J]. Nat Aging, 2021, 1(9):
769-782.
[15]KHOSLA S, FARR J N, TCHKONIA T, et al.
The role of cellular senescence in ageing and endocrine
disease[J]. Nat Rev Endocrinol, 2020,16(5):263-275.
[16]CHINI C, PECLAT T R, WARNER G M, et al.
CD38 ecto-enzyme in immune cells is induced during aging
and regulates NAD(+) and NMN levels[J]. Nat Metab, 2020,
2(11): 1284-1304.
[17]WISSLER GERDES E O, ZHU Y, WEIGAND B
M, et al. Cellular senescence in aging and age-related diseases:
Implications for neurodegenerative diseases[J]. Int RevNeurobiol, 2020,155:203-234.
[18]HUANG C, WANG Y, LI X, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan,
China[J]. Lancet, 2020, 395(10223):497-506.
[19]WANG D, HU B, HU C, et al. Clinical
Characteristics of 138 Hospitalized Patients With 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China[J].
JAMA, 2020, 323(11):1061-1069.
[20]唐新宁，董国伟，钟英成，等.淋巴细胞亚群及
炎症因子对新型冠状病毒肺炎患者的临床价值研究[J].标
记免疫分析与临床，2023，30（1）：25-29.
[21]CHEN N, ZHOU M, DONG X, et al.
Epidemiological and clinical characteristics of 99 cases of 2019
novel coronavirus pneumonia in Wuhan, China: a descriptive
study[J]. Lancet, 2020, 395(10223): 507-513.
[22]李松，汤庆.重型新型冠状病毒肺炎与普通重症
肺炎患者炎症因子水平分析[J].检验医学与临床，2021，
18（17）：2504-2507.
[23]STANFORD MEDICAL SCIENTIST TRAINING
PROGRAM S U S O M, STANFORD C A, USA., et al. A
single-cell atlas of the peripheral immune response in patients
with severe COVID-19[J]. Nat Med, 2020,26(7):1070-1076.
[24]TONIATI P, PIVA S, CATTALINI M, et al.
Tocilizumab for the treatment of severe COVID-19
pneumonia with hyperinflammatory syndrome and acute
respiratory failure: A single center study of 100 patients in
Brescia, Italy[J]. Autoimmun Rev, 2020,19(7): 102568.
[25]STONE J H, FRIGAULT M J, SERLING-BOYD
N J, et al. Efficacy of Tocilizumab in Patients Hospitalized
with Covid-19[J]. N Engl J Med, 2020,383(24): 2333-2344.
[26]FERNáNDEZ-RUIZ M, LóPEZ-MEDRANO
F, PéREZ-JACOISTE ASíN M A, et al. Tocilizumab
for the treatment of adult patients with severe COVID-19
pneumonia: A single-center cohort study[J]. J Med Virol,
2021, 93(2): 831-842.
[27]CAMELL C D, YOUSEFZADEH M J, ZHU Y,
et al. Senolytics reduce coronavirus-related mortality in old
mice[J]. Science, 2021, 373(6552): eabe4832.
[28]PIETROBON A J, TEIXEIRA F, SATO M N. I
mmunosenescence and Inflammaging: Risk Factors of Severe
COVID-19 in Older People[J]. Front Immunol, 2020, 11:
579220.
[29]BANI ć M, PLEšKO S, UREK M, et al.
Immunosenescence, Inflammaging and Resilience: An
Evolutionary Perspective of Adaptation in the Light of
COVID-19 Pandemic[J]. Psychiatr Danub, 2021, 33(Suppl
4): 427-431.
[30]WANG W, THOMAS R, OH J, et al. Thymic
Aging May Be Associated with COVID-19 Pathophysiology
in the Elderly[J]. Cells, 2021,10(3): 628.
[31]JUNQUEIRA C, CRESPO Â, RANJBAR S, et
al. FcγR-mediated SARS-CoV-2 infection of monocytes
activates inflammation[J]. Nature, 2022, 606(7914): 576-584.
[32]D'AGNILLO F, WALTERS K A, XIAO Y, et al.
Lung epithelial and endothelial damage, loss of tissue repair,
inhibition of fibrinolysis, and cellular senescence in fatal
COVID-19[J]. Sci Transl Med, 2021, 13(620): eabj7790.
[33]RADERMECKER C, DETREMBLEUR N,
GUIOT J, et al. Neutrophil extracellular traps infiltrate the
lung airway, interstitial, and vascular compartments in severe
COVID-19[J]. J Exp Med, 2020,217(12):e20201012.
[34]WISSLER GERDES E O, VANICHKACHORN
G, VERDOORN B P, et al. Role of senescence in the
chronic health consequences of COVID-19[J]. Transl Res,
2022, 241: 96-108.
[35]刘永梅，郑双丽，陈丹瑛，等.淋巴细胞抗原6
复合物基因座E抑制新型冠状病毒不同变异株刺突蛋白
介导的感染侵入[J].首都医科大学学报，2023，44（04）：
652-662.
[36]MELMS J C, BIERMANN J, HUANG H, et al.
A molecular single-cell lung atlas of lethal COVID-19[J].
Nature, 2021, 595(7865): 114-119.
[37]LAING A G, LORENC A, DEL MOLINO DEL
BARRIO I, et al. Author Correction: A dynamic COVID-
19 immune signature includes associations with poor
prognosis[J]. Nat Med, 2020, 26(12):1951.
[38]SCHERLINGER M, FELTEN R, GALLAIS F, et
al. Refining “Long-COVID” by a Prospective Multimodal
Evaluation of Patients with Long-Term Symptoms Attributed
to SARS-CoV-2 Infection[J]. Infect Dis Ther, 2021, 10(3):
1747-1763.
[39]MOSCHONAS I C, TSELEPIS A D. SARSCoV-2 infection and thrombotic complications: a narrative
review[J]. J Thromb Thrombolysis, 2021(5)[40]ASHTON R E, ANSDELL P, HUME E, et al.
COVID-19 and the long-term cardio-respiratory and
metabolic health complications[J]. Rev Cardiovasc Med,
2022,23 2
[41]SOARES P, RUIVINHO C, LOBO M J, et al.
Long-term cardiovascular events in individuals hospitalised
with COVID-19: a retrospective cohort[J]. Eur J Public
Health, 2024(Supplement_3): Supplement_3.
[42]MAGRO C, MULVEY J J, BERLIN D, et al.
Complement associated microvascular injury and thrombosis
in the pathogenesis of severe COVID-19 infection: A report
of five cases[J]. Transl Res, 2020,220:1-13.
[43]LENG A, SHAH M, AHMAD S A, et al.
Pathogenesis Underlying Neurological Manifestations of Long
COVID Syndrome and Potential Therapeutics[J]. Cells, 2023,
12(5): 816.
[44]仝小林，李修洋，赵林华，等.从“寒湿疫”角
度探讨新型冠状病毒肺炎的中医药防治策略[J].中医杂
志，2020，61（6）：465-470，前插1.
[45]熊继柏.国医大师熊继柏谈《湖南省新型冠状病
毒肺炎中医药诊疗方案》[J].湖南中医药大学学报，2020，
40（02）：123-128.
[46]马运涛，王斌，吴深涛.吴深涛教授从“浊毒
疫”论治新型冠状病毒肺炎临证体会[J].天津中医药，
2021，38（08）：966-970.
[47]蔡 梦 圆， 吴 澎 泞， 杨 仁 旭， 等.“肺 脾 同 治 ”
法在新型冠状病毒肺炎中的应用[J].中药药理与临床，
2020，36（02）：63-66.
[48]唐丽娟，何伟炎，金连顺，等.张忠德采用平调
五脏法辨治新型冠状病毒感染后长期症状经验[J].广州中
医药大学学报，2024，41（10）：2591-2595.
[49]赵梦雪，周艳杰，徐魏钦，等.王邦才从五脏论
治新型冠状病毒感染后遗症经验介绍[J].新中医，2024，
56（4）：212-216.
[50]黄永恒，谭惠璇，邹凤娇，等.基于中医药理论
及经典方药论新型冠状病毒肺炎康复期后遗症的治疗[J].
按摩与康复医学，2022（013-010）
[51]封俊辰，王华，赵丽，等.基于“主客交”理论
论治老年群体新型冠状病毒感染后状态[J].中华中医药杂
志，2023，38（10）：4575-4578.
[52]刘鹏，刘文甜，姚耿圳，等.邹旭治疗长新冠综
合征经验介绍[J].新中医，2024，56（16）：195-199.
[53]范逸品，王燕平，张华敏，等.试析从寒疫论治
新型冠状病毒肺炎[J].中医杂志，2020（5）：6.
[54]王刚，金劲松.新型冠状病毒肺炎中医认识初探
[J].天津中医药，2020
[55]范伏元，樊新荣，王莘智，等.从“湿毒夹燥”
谈湖南新型冠状病毒感染的肺炎的中医特点及防治[J].中
医杂志，2020，61（7）：4.
[56]李晓凤，杜武勋.基于五运六气理论对新型冠状
病毒感染肺炎的几点思考[J].中华中医药学刊，2020，38
（3）：4.
[57]赵四林，柳玉佳，范伏元，等.新型冠状病毒肺
炎重症，危重症恢复期患者的中医药治疗策略[J].湖南中
医药大学学报，2020，40（4）：5.
[58]张佳，陆雪琴，童文静，等.新型冠状病毒感染
中医证型与淋巴细胞计数及其年龄的相关性研究[J].辽宁
中医杂志，2023，50（8）：124-128.
[59]张平，潘广涛.清肺排毒汤改善新型冠状病毒肺
炎危重型患者炎性细胞因子的临床研究[J].世界科学技
术-中医药现代化，2021，23（02）：391-395.
[60]兰俊，樊恭春，孟龙.祛湿排毒扶正方治疗寒
湿郁肺证和疫毒闭肺证新型冠状病毒肺炎的临床疗效及
机制探讨[J].中国中西医结合急救杂志，2020，27（3）：
262-266.
[61]范梦月，刘静，孙蓉.藿朴夏苓汤治疗早期新型
冠状病毒肺炎（COVID-19）湿邪郁肺证物质基础及功
效的网络分析[J].中草药，2020，51（9）：2297-2306.
[62]王毅，李翔，张俊华，等.基于网络药理学的宣
肺败毒汤治疗新型冠状病毒肺炎机制研究[J].中国中药杂
志，2020，45（10）：2249-2256.
[63]刘清泉，夏文广，安长青，等.中西医结合治疗
新型冠状病毒肺炎作用的思考[J].中医杂志，2020，61
（06）：463-464.
[64]鲍婷婷，李修洋，王凡，等.从“寒湿人营”论
治危重型新型冠状病毒感染合并多器官功能障碍1例[J].
中医杂志，2023，64（23）：2461-2465.
[65]陆培培，闫思雨，郭轩彤，等.基于中医“气血
理论”论治新型冠状病毒感染后综合征[J].中西医结合心
脑血管病杂志，2024，22（12）：2285-2289.
[66]崔海兰，高伟，朱婷婷，等.史载祥运用升陷
三甲复脉汤治疗长新冠心悸胸闷经验[J].北京中医药，
2024，43（03）：283-285.
[67]徐忠德，陈智慧，张会永，等.运用三甲散加减
治疗高龄人群“长新冠”后心肺疾患[J].实用中医内科杂
志，2024，38（08）：124-126.
Refbacks
- 当前没有refback。
